CN109718311B - 一种直肠滴注治疗湿热瘀阻型慢性前列腺炎的中药 - Google Patents
一种直肠滴注治疗湿热瘀阻型慢性前列腺炎的中药 Download PDFInfo
- Publication number
- CN109718311B CN109718311B CN201910215999.4A CN201910215999A CN109718311B CN 109718311 B CN109718311 B CN 109718311B CN 201910215999 A CN201910215999 A CN 201910215999A CN 109718311 B CN109718311 B CN 109718311B
- Authority
- CN
- China
- Prior art keywords
- mixture
- decocted
- minutes
- damp
- chinese medicine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000003814 drug Substances 0.000 title claims abstract description 76
- 201000007094 prostatitis Diseases 0.000 title claims abstract description 51
- 208000013507 chronic prostatitis Diseases 0.000 title claims abstract description 32
- 239000000203 mixture Substances 0.000 claims abstract description 32
- 229940079593 drug Drugs 0.000 claims abstract description 26
- 239000002994 raw material Substances 0.000 claims abstract description 26
- 244000223760 Cinnamomum zeylanicum Species 0.000 claims abstract description 18
- 235000017803 cinnamon Nutrition 0.000 claims abstract description 18
- 241000218176 Corydalis Species 0.000 claims abstract description 14
- 235000006484 Paeonia officinalis Nutrition 0.000 claims abstract description 14
- 235000007212 Verbena X moechina Moldenke Nutrition 0.000 claims abstract description 14
- 240000001519 Verbena officinalis Species 0.000 claims abstract description 14
- 235000001594 Verbena polystachya Kunth Nutrition 0.000 claims abstract description 14
- 235000007200 Verbena x perriana Moldenke Nutrition 0.000 claims abstract description 14
- 235000002270 Verbena x stuprosa Moldenke Nutrition 0.000 claims abstract description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 13
- 241000691155 Pteris multifida Species 0.000 claims abstract description 11
- 239000000706 filtrate Substances 0.000 claims abstract description 11
- 240000007371 Cuscuta campestris Species 0.000 claims abstract description 7
- 238000001914 filtration Methods 0.000 claims abstract description 5
- 210000004369 blood Anatomy 0.000 claims description 35
- 239000008280 blood Substances 0.000 claims description 35
- 210000000582 semen Anatomy 0.000 claims description 17
- 241001106477 Paeoniaceae Species 0.000 claims description 12
- 241000233948 Typha Species 0.000 claims description 12
- 238000009835 boiling Methods 0.000 claims description 7
- 230000000694 effects Effects 0.000 abstract description 26
- 238000000034 method Methods 0.000 abstract description 17
- 231100000957 no side effect Toxicity 0.000 abstract description 2
- 244000170916 Paeonia officinalis Species 0.000 abstract 1
- 240000001398 Typha domingensis Species 0.000 abstract 1
- 238000011282 treatment Methods 0.000 description 33
- 208000002193 Pain Diseases 0.000 description 27
- 230000036407 pain Effects 0.000 description 27
- 208000024891 symptom Diseases 0.000 description 27
- 210000002700 urine Anatomy 0.000 description 14
- 238000011160 research Methods 0.000 description 13
- 230000027939 micturition Effects 0.000 description 12
- 230000008961 swelling Effects 0.000 description 12
- 210000004185 liver Anatomy 0.000 description 10
- 210000000265 leukocyte Anatomy 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- 210000003734 kidney Anatomy 0.000 description 8
- 208000004880 Polyuria Diseases 0.000 description 7
- 210000001015 abdomen Anatomy 0.000 description 7
- 230000017531 blood circulation Effects 0.000 description 7
- 238000003745 diagnosis Methods 0.000 description 7
- 210000002640 perineum Anatomy 0.000 description 7
- 230000000144 pharmacologic effect Effects 0.000 description 7
- 230000001737 promoting effect Effects 0.000 description 7
- 210000002307 prostate Anatomy 0.000 description 7
- VRSRXLJTYQVOHC-YEJXKQKISA-N corydaline Chemical compound C=1([C@H]2[C@H]3C)C=C(OC)C(OC)=CC=1CCN2CC1=C3C=CC(OC)=C1OC VRSRXLJTYQVOHC-YEJXKQKISA-N 0.000 description 6
- 230000007812 deficiency Effects 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 230000035619 diuresis Effects 0.000 description 6
- 238000001035 drying Methods 0.000 description 6
- 210000000952 spleen Anatomy 0.000 description 6
- 208000011580 syndromic disease Diseases 0.000 description 6
- 201000000736 Amenorrhea Diseases 0.000 description 5
- 206010001928 Amenorrhoea Diseases 0.000 description 5
- 231100000540 amenorrhea Toxicity 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 238000009826 distribution Methods 0.000 description 5
- 206010013990 dysuria Diseases 0.000 description 5
- 235000019640 taste Nutrition 0.000 description 5
- 206010067484 Adverse reaction Diseases 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 4
- 206010007247 Carbuncle Diseases 0.000 description 4
- RFKQJTRWODZPHF-UHFFFAOYSA-N Dehydrocorydaline Chemical compound COC1=C(OC)C=C2CC[N+]3=CC4=C(OC)C(OC)=CC=C4C(C)=C3C2=C1 RFKQJTRWODZPHF-UHFFFAOYSA-N 0.000 description 4
- 208000005171 Dysmenorrhea Diseases 0.000 description 4
- 206010013935 Dysmenorrhoea Diseases 0.000 description 4
- 206010030113 Oedema Diseases 0.000 description 4
- YKRGDOXKVOZESV-WRJNSLSBSA-N Paeoniflorin Chemical compound C([C@]12[C@H]3O[C@]4(O)C[C@](O3)([C@]1(C[C@@H]42)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)C)OC(=O)C1=CC=CC=C1 YKRGDOXKVOZESV-WRJNSLSBSA-N 0.000 description 4
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 4
- 230000006838 adverse reaction Effects 0.000 description 4
- 239000012530 fluid Substances 0.000 description 4
- 210000001624 hip Anatomy 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 230000007774 longterm Effects 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- YKRGDOXKVOZESV-UHFFFAOYSA-N paeoniflorin Natural products O1C(C)(C2(CC34)OC5C(C(O)C(O)C(CO)O5)O)CC3(O)OC1C24COC(=O)C1=CC=CC=C1 YKRGDOXKVOZESV-UHFFFAOYSA-N 0.000 description 4
- 231100000331 toxic Toxicity 0.000 description 4
- 230000002588 toxic effect Effects 0.000 description 4
- 210000003708 urethra Anatomy 0.000 description 4
- VRSRXLJTYQVOHC-UHFFFAOYSA-N Corydaline Natural products CC1C2C=3C=C(OC)C(OC)=CC=3CCN2CC2=C1C=CC(OC)=C2OC VRSRXLJTYQVOHC-UHFFFAOYSA-N 0.000 description 3
- 206010012735 Diarrhoea Diseases 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- 208000034507 Haematemesis Diseases 0.000 description 3
- 208000032843 Hemorrhage Diseases 0.000 description 3
- 241000736199 Paeonia Species 0.000 description 3
- 244000236658 Paeonia lactiflora Species 0.000 description 3
- 235000008598 Paeonia lactiflora Nutrition 0.000 description 3
- 206010033372 Pain and discomfort Diseases 0.000 description 3
- 206010036968 Prostatic pain Diseases 0.000 description 3
- 206010042674 Swelling Diseases 0.000 description 3
- 208000007536 Thrombosis Diseases 0.000 description 3
- 238000009825 accumulation Methods 0.000 description 3
- 230000003213 activating effect Effects 0.000 description 3
- 210000000436 anus Anatomy 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 235000019658 bitter taste Nutrition 0.000 description 3
- 208000034158 bleeding Diseases 0.000 description 3
- 230000000740 bleeding effect Effects 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- 235000009508 confectionery Nutrition 0.000 description 3
- 230000013872 defecation Effects 0.000 description 3
- 208000001780 epistaxis Diseases 0.000 description 3
- 210000004392 genitalia Anatomy 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 230000002757 inflammatory effect Effects 0.000 description 3
- 208000014674 injury Diseases 0.000 description 3
- 230000003908 liver function Effects 0.000 description 3
- 210000004706 scrotum Anatomy 0.000 description 3
- 230000008736 traumatic injury Effects 0.000 description 3
- WVTKBKWTSCPRNU-KYJUHHDHSA-N (+)-Tetrandrine Chemical compound C([C@H]1C=2C=C(C(=CC=2CCN1C)OC)O1)C(C=C2)=CC=C2OC(=C2)C(OC)=CC=C2C[C@@H]2N(C)CCC3=CC(OC)=C(OC)C1=C23 WVTKBKWTSCPRNU-KYJUHHDHSA-N 0.000 description 2
- UXYJCYXWJGAKQY-HNNXBMFYSA-N (S)-stylopine Chemical compound C1C2=C3OCOC3=CC=C2C[C@@H]2N1CCC1=C2C=C(OCO2)C2=C1 UXYJCYXWJGAKQY-HNNXBMFYSA-N 0.000 description 2
- AEQDJSLRWYMAQI-UHFFFAOYSA-N 2,3,9,10-tetramethoxy-6,8,13,13a-tetrahydro-5H-isoquinolino[2,1-b]isoquinoline Chemical compound C1CN2CC(C(=C(OC)C=C3)OC)=C3CC2C2=C1C=C(OC)C(OC)=C2 AEQDJSLRWYMAQI-UHFFFAOYSA-N 0.000 description 2
- 208000004998 Abdominal Pain Diseases 0.000 description 2
- 206010002198 Anaphylactic reaction Diseases 0.000 description 2
- 206010003694 Atrophy Diseases 0.000 description 2
- 241000193830 Bacillus <bacterium> Species 0.000 description 2
- 206010006784 Burning sensation Diseases 0.000 description 2
- 206010051625 Conjunctival hyperaemia Diseases 0.000 description 2
- 241000721047 Danaus plexippus Species 0.000 description 2
- 208000010228 Erectile Dysfunction Diseases 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 206010019909 Hernia Diseases 0.000 description 2
- 206010021143 Hypoxia Diseases 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 206010027514 Metrorrhagia Diseases 0.000 description 2
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 2
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 2
- 241000191967 Staphylococcus aureus Species 0.000 description 2
- 241001518821 Typha orientalis Species 0.000 description 2
- 208000025865 Ulcer Diseases 0.000 description 2
- 206010046555 Urinary retention Diseases 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 230000006578 abscission Effects 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
- 230000000202 analgesic effect Effects 0.000 description 2
- 238000000540 analysis of variance Methods 0.000 description 2
- 230000036783 anaphylactic response Effects 0.000 description 2
- 208000003455 anaphylaxis Diseases 0.000 description 2
- 208000010668 atopic eczema Diseases 0.000 description 2
- 230000037444 atrophy Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 238000005520 cutting process Methods 0.000 description 2
- 230000007717 exclusion Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 229930003935 flavonoid Natural products 0.000 description 2
- 150000002215 flavonoids Chemical class 0.000 description 2
- 235000017173 flavonoids Nutrition 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 210000004013 groin Anatomy 0.000 description 2
- 238000003306 harvesting Methods 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 201000001881 impotence Diseases 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 2
- 230000003907 kidney function Effects 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 208000017497 prostate disease Diseases 0.000 description 2
- 210000004908 prostatic fluid Anatomy 0.000 description 2
- GPTFURBXHJWNHR-UHFFFAOYSA-N protopine Chemical compound C1=C2C(=O)CC3=CC=C4OCOC4=C3CN(C)CCC2=CC2=C1OCO2 GPTFURBXHJWNHR-UHFFFAOYSA-N 0.000 description 2
- 235000005875 quercetin Nutrition 0.000 description 2
- 229960001285 quercetin Drugs 0.000 description 2
- 238000007873 sieving Methods 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 238000005728 strengthening Methods 0.000 description 2
- 238000012353 t test Methods 0.000 description 2
- 210000001550 testis Anatomy 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 229940126680 traditional chinese medicines Drugs 0.000 description 2
- 208000019206 urinary tract infection Diseases 0.000 description 2
- QQPCNRKHGFIVLH-UHFFFAOYSA-N (10S,11S)-Pterosin Natural products CC1=C(CCO)C(C)=C2C(=O)C(C)C(O)C2=C1 QQPCNRKHGFIVLH-UHFFFAOYSA-N 0.000 description 1
- SJNCSXMTBXDZQA-SECBINFHSA-N (2r)-6-(2-hydroxyethyl)-2,5,7-trimethyl-2,3-dihydroinden-1-one Chemical compound CC1=C(CCO)C(C)=C2C(=O)[C@H](C)CC2=C1 SJNCSXMTBXDZQA-SECBINFHSA-N 0.000 description 1
- SDOFMBGMRVAJNF-KVTDHHQDSA-N (2r,3r,4r,5r)-6-aminohexane-1,2,3,4,5-pentol Chemical compound NC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO SDOFMBGMRVAJNF-KVTDHHQDSA-N 0.000 description 1
- VKDMMOFAMUXTQZ-VTNBQNSRSA-N (2s,3s)-3-hydroxy-2,5,7-trimethyl-6-[2-[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyethyl]-2,3-dihydroinden-1-one Chemical compound C1([C@@H](O)[C@@H](C(C1=C1C)=O)C)=CC(C)=C1CCO[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VKDMMOFAMUXTQZ-VTNBQNSRSA-N 0.000 description 1
- WCGUUGGRBIKTOS-GPOJBZKASA-N (3beta)-3-hydroxyurs-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C)[C@H](C)[C@H]5C4=CC[C@@H]3[C@]21C WCGUUGGRBIKTOS-GPOJBZKASA-N 0.000 description 1
- KJPRLNWUNMBNBZ-QPJJXVBHSA-N (E)-cinnamaldehyde Chemical compound O=C\C=C\C1=CC=CC=C1 KJPRLNWUNMBNBZ-QPJJXVBHSA-N 0.000 description 1
- FTVWIRXFELQLPI-ZDUSSCGKSA-N (S)-naringenin Chemical compound C1=CC(O)=CC=C1[C@H]1OC2=CC(O)=CC(O)=C2C(=O)C1 FTVWIRXFELQLPI-ZDUSSCGKSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- JRJGKUTZNBZHNK-UHFFFAOYSA-N 3-phenylpropyl acetate Chemical compound CC(=O)OCCCC1=CC=CC=C1 JRJGKUTZNBZHNK-UHFFFAOYSA-N 0.000 description 1
- LATYEZNGPQKAIK-UHFFFAOYSA-N 6'-O-benzoylpaeoniflorin Natural products O1C(C)(C2(CC34)OC5C(C(O)C(O)C(COC(=O)C=6C=CC=CC=6)O5)O)CC3(O)OC1C24COC(=O)C1=CC=CC=C1 LATYEZNGPQKAIK-UHFFFAOYSA-N 0.000 description 1
- IVCZEZUJCMWBBR-UHFFFAOYSA-N 7-O-beta-D-glucopyranosyl-7,3',4'-trihydroxyflavone Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C2C(=O)C=C(C=3C=C(O)C(O)=CC=3)OC2=C1 IVCZEZUJCMWBBR-UHFFFAOYSA-N 0.000 description 1
- 206010000077 Abdominal mass Diseases 0.000 description 1
- 206010000084 Abdominal pain lower Diseases 0.000 description 1
- 206010000234 Abortion spontaneous Diseases 0.000 description 1
- 206010000242 Abortion threatened Diseases 0.000 description 1
- 206010002660 Anoxia Diseases 0.000 description 1
- 241000976983 Anoxia Species 0.000 description 1
- KMOUJOKENFFTPU-UHFFFAOYSA-N Apigenin-7-glucosid Natural products OC1C(O)C(O)C(CO)OC1OC1=CC(O)=C2C(=O)C=C(C=3C=CC(O)=CC=3)OC2=C1 KMOUJOKENFFTPU-UHFFFAOYSA-N 0.000 description 1
- 240000007087 Apium graveolens Species 0.000 description 1
- 235000015849 Apium graveolens Dulce Group Nutrition 0.000 description 1
- 235000010591 Appio Nutrition 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Natural products OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 208000004429 Bacillary Dysentery Diseases 0.000 description 1
- 208000008035 Back Pain Diseases 0.000 description 1
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 description 1
- LATYEZNGPQKAIK-HRCYFWENSA-N Benzoylpaeoniflorin Chemical compound C([C@]12[C@H]3O[C@]4(O)C[C@](O3)([C@]1(C[C@@H]42)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](COC(=O)C=2C=CC=CC=2)O1)O)C)OC(=O)C1=CC=CC=C1 LATYEZNGPQKAIK-HRCYFWENSA-N 0.000 description 1
- 206010057687 Bloody discharge Diseases 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- 208000031868 Calculus ureteric Diseases 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 244000037364 Cinnamomum aromaticum Species 0.000 description 1
- 235000014489 Cinnamomum aromaticum Nutrition 0.000 description 1
- 241000252804 Cinnamomum insularimontanum Species 0.000 description 1
- 206010010726 Conjunctival oedema Diseases 0.000 description 1
- 241000207782 Convolvulaceae Species 0.000 description 1
- XDVZNDLANFJOQR-UHFFFAOYSA-N Coptisine Natural products O=Cc1c2OCOc2ccc1C=C3/NCCc4cc5OCOc5cc34 XDVZNDLANFJOQR-UHFFFAOYSA-N 0.000 description 1
- 241000510672 Cuminum Species 0.000 description 1
- 241001124144 Dermaptera Species 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 206010013647 Drowning Diseases 0.000 description 1
- 206010014080 Ecchymosis Diseases 0.000 description 1
- 208000004232 Enteritis Diseases 0.000 description 1
- 208000008967 Enuresis Diseases 0.000 description 1
- 241000893536 Epimedium Species 0.000 description 1
- 208000015220 Febrile disease Diseases 0.000 description 1
- 206010017915 Gastroenteritis shigella Diseases 0.000 description 1
- 208000012671 Gastrointestinal haemorrhages Diseases 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- 206010018612 Gonorrhoea Diseases 0.000 description 1
- 238000003794 Gram staining Methods 0.000 description 1
- 241000558306 Gynocardia odorata Species 0.000 description 1
- 208000000616 Hemoptysis Diseases 0.000 description 1
- OVSQVDMCBVZWGM-SJWGPRHPSA-N Hyperin Natural products O[C@H]1[C@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=C(C=2C=C(O)C(O)=CC=2)OC2=CC(O)=CC(O)=C2C1=O OVSQVDMCBVZWGM-SJWGPRHPSA-N 0.000 description 1
- FVQOMEDMFUMIMO-UHFFFAOYSA-N Hyperosid Natural products OC1C(O)C(O)C(CO)OC1OC1C(=O)C2=C(O)C=C(O)C=C2OC1C1=CC=C(O)C(O)=C1 FVQOMEDMFUMIMO-UHFFFAOYSA-N 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010021118 Hypotonia Diseases 0.000 description 1
- GQODBWLKUWYOFX-UHFFFAOYSA-N Isorhamnetin Natural products C1=C(O)C(C)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 GQODBWLKUWYOFX-UHFFFAOYSA-N 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- 241000218195 Lauraceae Species 0.000 description 1
- GSDSWSVVBLHKDQ-JTQLQIEISA-N Levofloxacin Chemical compound C([C@@H](N1C2=C(C(C(C(O)=O)=C1)=O)C=C1F)C)OC2=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-JTQLQIEISA-N 0.000 description 1
- 241000045552 Longidorus orientalis Species 0.000 description 1
- 208000008930 Low Back Pain Diseases 0.000 description 1
- 238000000585 Mann–Whitney U test Methods 0.000 description 1
- 241000187479 Mycobacterium tuberculosis Species 0.000 description 1
- 208000000693 Neurogenic Urinary Bladder Diseases 0.000 description 1
- 206010029279 Neurogenic bladder Diseases 0.000 description 1
- 206010029333 Neurosis Diseases 0.000 description 1
- 206010059013 Nocturnal emission Diseases 0.000 description 1
- 241000124464 Paeonia veitchii Species 0.000 description 1
- 241000218180 Papaveraceae Species 0.000 description 1
- 206010034038 Parotitis Diseases 0.000 description 1
- 208000031481 Pathologic Constriction Diseases 0.000 description 1
- 208000000450 Pelvic Pain Diseases 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- 244000064622 Physalis edulis Species 0.000 description 1
- YPWHZCPMOQGCDQ-UHFFFAOYSA-N Populnin Natural products OC1C(O)C(O)C(CO)OC1OC1=CC(O)=C2C(=O)C(O)=C(C=3C=CC(O)=CC=3)OC2=C1 YPWHZCPMOQGCDQ-UHFFFAOYSA-N 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000004403 Prostatic Hyperplasia Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- GTRPODKMSBFDOI-UHFFFAOYSA-N Protopine Natural products CN1Cc2c3OCOc3ccc2C4C1Cc5cc6OCOc6cc5C4=O GTRPODKMSBFDOI-UHFFFAOYSA-N 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- ZAALQOFZFANFTF-UHFFFAOYSA-N Pseudoprotipine Natural products C1=C2C(=O)CC3=CC=4OCOC=4C=C3CN(C)CCC2=CC2=C1OCO2 ZAALQOFZFANFTF-UHFFFAOYSA-N 0.000 description 1
- 208000028017 Psychotic disease Diseases 0.000 description 1
- 241000736301 Pteridaceae Species 0.000 description 1
- GTPYMQNYDRMGEN-UHFFFAOYSA-N Pterosin C-3-O-glucoside Natural products C12=CC(C)=C(CCO)C(C)=C2C(=O)C(C)C1OC1OC(CO)C(O)C(O)C1O GTPYMQNYDRMGEN-UHFFFAOYSA-N 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 241000218201 Ranunculaceae Species 0.000 description 1
- 241000245165 Rhododendron ponticum Species 0.000 description 1
- 241001417495 Serranidae Species 0.000 description 1
- 201000001880 Sexual dysfunction Diseases 0.000 description 1
- 241000607768 Shigella Species 0.000 description 1
- 241000607764 Shigella dysenteriae Species 0.000 description 1
- 241000607762 Shigella flexneri Species 0.000 description 1
- 244000303286 Stachys officinalis Species 0.000 description 1
- 235000009225 Stachys officinalis Nutrition 0.000 description 1
- 208000005985 Threatened Abortion Diseases 0.000 description 1
- 208000009205 Tinnitus Diseases 0.000 description 1
- 206010053476 Traumatic haemorrhage Diseases 0.000 description 1
- 241000233945 Typhaceae Species 0.000 description 1
- 208000037386 Typhoid Diseases 0.000 description 1
- 208000000014 Ureteral Calculi Diseases 0.000 description 1
- 241001073567 Verbenaceae Species 0.000 description 1
- 206010047513 Vision blurred Diseases 0.000 description 1
- 206010047642 Vitiligo Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 208000031975 Yang Deficiency Diseases 0.000 description 1
- 208000031971 Yin Deficiency Diseases 0.000 description 1
- 206010000059 abdominal discomfort Diseases 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- 230000001919 adrenal effect Effects 0.000 description 1
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- NGFLTEGALWMQIJ-UHFFFAOYSA-N allocryptopine Natural products COc1ccc2CC(=O)c3cc4OCOc4cc3CN(C)CCc2c1OC NGFLTEGALWMQIJ-UHFFFAOYSA-N 0.000 description 1
- HYBRYAPKQCZIAE-UHFFFAOYSA-N allocryptopine Chemical compound C1=C2CCN(C)CC3=C(OC)C(OC)=CC=C3CC(=O)C2=CC2=C1OCO2 HYBRYAPKQCZIAE-UHFFFAOYSA-N 0.000 description 1
- VIWQCBZFJFSCLC-UHFFFAOYSA-N alpha-benzoyloxypaeoniflorin Natural products O1C(C)(C2(CC34)OC5C(C(O)C(O)C(COC(=O)C=6C=CC=CC=6)O5)O)CC3(O)OC1C24COC(=O)C1=CC=C(O)C=C1 VIWQCBZFJFSCLC-UHFFFAOYSA-N 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000000954 anitussive effect Effects 0.000 description 1
- 230000007953 anoxia Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 229940124584 antitussives Drugs 0.000 description 1
- KMOUJOKENFFTPU-QNDFHXLGSA-N apigenin 7-O-beta-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=C2C(=O)C=C(C=3C=CC(O)=CC=3)OC2=C1 KMOUJOKENFFTPU-QNDFHXLGSA-N 0.000 description 1
- 229930191701 arteannuin Natural products 0.000 description 1
- BLUAFEHZUWYNDE-NNWCWBAJSA-N artemisinin Chemical compound C([C@](OO1)(C)O2)C[C@H]3[C@H](C)CC[C@@H]4[C@@]31[C@@H]2OC(=O)[C@@H]4C BLUAFEHZUWYNDE-NNWCWBAJSA-N 0.000 description 1
- 229960004191 artemisinin Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- RJWJHRPNHPHBRN-FKVJWERZSA-N aucubin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@H]1[C@@H]2C(CO)=C[C@@H](O)[C@@H]2C=CO1 RJWJHRPNHPHBRN-FKVJWERZSA-N 0.000 description 1
- UTDFQMAXCUGNJR-UHFFFAOYSA-N aucubin Natural products OCC1OC(Oc2ccoc2C3C(O)CCC3O)C(O)C(O)C1O UTDFQMAXCUGNJR-UHFFFAOYSA-N 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 229940076810 beta sitosterol Drugs 0.000 description 1
- LGJMUZUPVCAVPU-UHFFFAOYSA-N beta-Sitostanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CC)C(C)C)C1(C)CC2 LGJMUZUPVCAVPU-UHFFFAOYSA-N 0.000 description 1
- 235000013734 beta-carotene Nutrition 0.000 description 1
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 description 1
- 239000011648 beta-carotene Substances 0.000 description 1
- NJKOMDUNNDKEAI-UHFFFAOYSA-N beta-sitosterol Natural products CCC(CCC(C)C1CCC2(C)C3CC=C4CC(O)CCC4C3CCC12C)C(C)C NJKOMDUNNDKEAI-UHFFFAOYSA-N 0.000 description 1
- 229960002747 betacarotene Drugs 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- KJPRLNWUNMBNBZ-UHFFFAOYSA-N cinnamic aldehyde Natural products O=CC=CC1=CC=CC=C1 KJPRLNWUNMBNBZ-UHFFFAOYSA-N 0.000 description 1
- 229940117916 cinnamic aldehyde Drugs 0.000 description 1
- 239000010630 cinnamon oil Substances 0.000 description 1
- WJSDHUCWMSHDCR-VMPITWQZSA-N cinnamyl acetate Natural products CC(=O)OC\C=C\C1=CC=CC=C1 WJSDHUCWMSHDCR-VMPITWQZSA-N 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- XYHOBCMEDLZUMP-UHFFFAOYSA-N coptisine Chemical compound C1=C2C=C(C3=C(C=C4OCOC4=C3)CC3)[N+]3=CC2=C2OCOC2=C1 XYHOBCMEDLZUMP-UHFFFAOYSA-N 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- CHWPMFMUQATVNK-ARYYTZDLSA-N dihydrosporogen AO-1 Natural products O[C@H]1[C@]2(C(C)=C)O[C@@H]2[C@]2(C)[C@@H](C)[C@H](O)CCC2=C1 CHWPMFMUQATVNK-ARYYTZDLSA-N 0.000 description 1
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical compound C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 description 1
- 206010013023 diphtheria Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- UKIOTQZYKUPESG-UHFFFAOYSA-N dl-Tetrahydrocoptisine Natural products C1=C2C(C)C3C4=CC(OCO5)=C5C=C4CCN3CC2=C2OCOC2=C1 UKIOTQZYKUPESG-UHFFFAOYSA-N 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 201000010063 epididymitis Diseases 0.000 description 1
- 235000018905 epimedium Nutrition 0.000 description 1
- 239000002389 essential drug Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000004299 exfoliation Methods 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 208000017561 flaccidity Diseases 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 208000018997 giddiness Diseases 0.000 description 1
- 208000007565 gingivitis Diseases 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 208000001786 gonorrhea Diseases 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 208000035861 hematochezia Diseases 0.000 description 1
- 210000000777 hematopoietic system Anatomy 0.000 description 1
- 208000006750 hematuria Diseases 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- NQYPTLKGQJDGTI-FCVRJVSHSA-N hyperoside Natural products OC[C@H]1O[C@@H](OC2=C(Oc3cc(O)cc(O)c3[C@H]2O)c4ccc(O)c(O)c4)[C@H](O)[C@@H](O)[C@H]1O NQYPTLKGQJDGTI-FCVRJVSHSA-N 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- IZQSVPBOUDKVDZ-UHFFFAOYSA-N isorhamnetin Chemical compound C1=C(O)C(OC)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 IZQSVPBOUDKVDZ-UHFFFAOYSA-N 0.000 description 1
- 235000008800 isorhamnetin Nutrition 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 238000009592 kidney function test Methods 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- TYQCGQRIZGCHNB-JLAZNSOCSA-N l-ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(O)=C(O)C1=O TYQCGQRIZGCHNB-JLAZNSOCSA-N 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 201000002364 leukopenia Diseases 0.000 description 1
- 231100001022 leukopenia Toxicity 0.000 description 1
- 229960003376 levofloxacin Drugs 0.000 description 1
- 238000007449 liver function test Methods 0.000 description 1
- 210000004705 lumbosacral region Anatomy 0.000 description 1
- MQYXUWHLBZFQQO-QGTGJCAVSA-N lupeol Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C)CC[C@@H](C(=C)C)[C@@H]5[C@H]4CC[C@@H]3[C@]21C MQYXUWHLBZFQQO-QGTGJCAVSA-N 0.000 description 1
- PKGKOZOYXQMJNG-UHFFFAOYSA-N lupeol Natural products CC(=C)C1CC2C(C)(CCC3C4(C)CCC5C(C)(C)C(O)CCC5(C)C4CCC23C)C1 PKGKOZOYXQMJNG-UHFFFAOYSA-N 0.000 description 1
- PEFNSGRTCBGNAN-QNDFHXLGSA-N luteolin 7-O-beta-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=C2C(=O)C=C(C=3C=C(O)C(O)=CC=3)OC2=C1 PEFNSGRTCBGNAN-QNDFHXLGSA-N 0.000 description 1
- QZOVLVSTWSTHQN-UHFFFAOYSA-N luteolin 7-O-glucoside Natural products OCC1OC(Oc2cc(O)c3C(=O)C=C(C(=O)c3c2)c4ccc(O)c(O)c4)C(O)C(O)C1O QZOVLVSTWSTHQN-UHFFFAOYSA-N 0.000 description 1
- KBGKQZVCLWKUDQ-UHFFFAOYSA-N luteolin-glucoside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC(O)=CC2=C1C(=O)C=C(C=1C=C(O)C(O)=CC=1)O2 KBGKQZVCLWKUDQ-UHFFFAOYSA-N 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000002398 materia medica Substances 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 208000015994 miscarriage Diseases 0.000 description 1
- WGEYAGZBLYNDFV-UHFFFAOYSA-N naringenin Natural products C1(=O)C2=C(O)C=C(O)C=C2OC(C1)C1=CC=C(CC1)O WGEYAGZBLYNDFV-UHFFFAOYSA-N 0.000 description 1
- 229940117954 naringenin Drugs 0.000 description 1
- 235000007625 naringenin Nutrition 0.000 description 1
- 208000015238 neurotic disease Diseases 0.000 description 1
- 238000001422 normality test Methods 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 238000007427 paired t-test Methods 0.000 description 1
- 238000002559 palpation Methods 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 210000004197 pelvis Anatomy 0.000 description 1
- 210000003899 penis Anatomy 0.000 description 1
- 238000001558 permutation test Methods 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 208000037920 primary disease Diseases 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 208000023958 prostate neoplasm Diseases 0.000 description 1
- 238000011471 prostatectomy Methods 0.000 description 1
- SJNCSXMTBXDZQA-UHFFFAOYSA-N pterosine B Natural products CC1=C(CCO)C(C)=C2C(=O)C(C)CC2=C1 SJNCSXMTBXDZQA-UHFFFAOYSA-N 0.000 description 1
- OVSQVDMCBVZWGM-DTGCRPNFSA-N quercetin 3-O-beta-D-galactopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=C(C=2C=C(O)C(O)=CC=2)OC2=CC(O)=CC(O)=C2C1=O OVSQVDMCBVZWGM-DTGCRPNFSA-N 0.000 description 1
- BBFYUPYFXSSMNV-UHFFFAOYSA-N quercetin-7-o-galactoside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC(O)=C2C(=O)C(O)=C(C=3C=C(O)C(O)=CC=3)OC2=C1 BBFYUPYFXSSMNV-UHFFFAOYSA-N 0.000 description 1
- WVTKBKWTSCPRNU-UHFFFAOYSA-N rac-Tetrandrin Natural products O1C(C(=CC=2CCN3C)OC)=CC=2C3CC(C=C2)=CC=C2OC(=C2)C(OC)=CC=C2CC2N(C)CCC3=CC(OC)=C(OC)C1=C23 WVTKBKWTSCPRNU-UHFFFAOYSA-N 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 239000011435 rock Substances 0.000 description 1
- 238000005096 rolling process Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000001624 sedative effect Effects 0.000 description 1
- 231100000872 sexual dysfunction Toxicity 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 201000005113 shigellosis Diseases 0.000 description 1
- KZJWDPNRJALLNS-VJSFXXLFSA-N sitosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]1(C)CC2 KZJWDPNRJALLNS-VJSFXXLFSA-N 0.000 description 1
- 229950005143 sitosterol Drugs 0.000 description 1
- 210000002356 skeleton Anatomy 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 208000000995 spontaneous abortion Diseases 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 230000036262 stenosis Effects 0.000 description 1
- 208000037804 stenosis Diseases 0.000 description 1
- 229910052572 stoneware Inorganic materials 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000009182 swimming Effects 0.000 description 1
- 230000009044 synergistic interaction Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 231100001274 therapeutic index Toxicity 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 231100000886 tinnitus Toxicity 0.000 description 1
- 206010044008 tonsillitis Diseases 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 201000008297 typhoid fever Diseases 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 208000014001 urinary system disease Diseases 0.000 description 1
- 210000001635 urinary tract Anatomy 0.000 description 1
- 229940096998 ursolic acid Drugs 0.000 description 1
- PLSAJKYPRJGMHO-UHFFFAOYSA-N ursolic acid Natural products CC1CCC2(CCC3(C)C(C=CC4C5(C)CCC(O)C(C)(C)C5CCC34C)C2C1C)C(=O)O PLSAJKYPRJGMHO-UHFFFAOYSA-N 0.000 description 1
- 201000004822 varicocele Diseases 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 229940126673 western medicines Drugs 0.000 description 1
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 1
Abstract
本发明涉及直肠滴注治疗湿热瘀阻型慢性前列腺炎的中药,可有效解决治疗湿热瘀阻型前列腺炎效果好,无副作用的用药问题,由以下原料药物制成:马鞭草30‑40g、凤尾草30‑40g,蒲黄30‑40g,元胡30‑40g,菟丝子30‑40g,肉桂5‑8g和赤芍25‑28g,将原料药物混合在一起,加水400‑600mL,室温浸泡25‑35分钟,武火煎至沸腾后,改为文火煎煮18‑22分钟,过滤,得滤液,即成。本发明采用纯天然的原料中药物制成,各种药物之间有机配合,协同增效,施药途径科学合理,原料丰富,方法简单,使用方便,疗效好,成本低,是直肠滴注治疗湿热瘀阻型慢性前列腺炎药物上的一大创新。
Description
技术领域
本发明涉及医药,特别是一种直肠滴注治疗湿热瘀阻型慢性前列腺炎的中药。
背景技术
慢性前列腺炎是好发于中青年男性的一种常见的泌尿系统疾病,目前研究表明,慢性前列腺炎不是单一的一种疾病,而是一组临床表现各异的综合征。通常根据Drach(1978年)的分类法将前列腺炎分为四种类型:急性细菌性前列腺炎(ABP)、慢性细菌性前列腺炎(CBP)、慢性非细菌性前列腺炎(CNP)及前列腺痛(PD)。随着研究的深入,人们发现这种以病因为基础的分类方法容易造成诊治上的混乱。为了弥补该分类方法的不足,美国国家卫生研究院(NIH)根据当时对前列腺炎的和临床研究情况,制定了一种新的分类方法即:Ⅰ型:相当于传统分类方法中的ABP。起病急,可表现为突发的发热性疾病,伴有明显的下尿路感染症状,尿液中白细胞数量升高,血液和(或)尿液中的细菌培养阳性。Ⅱ型:相当于传统分类方法中的CBP。有反复发作的下尿路感染症状,持续时间超过3个月,EPS/精液/VB3中白细胞数量升高,细菌培养结果呈阳性。Ⅲ型:慢性前列腺炎/慢性盆腔疼痛综合征,相当于传统分类方法中的CNP/PD,是前列腺炎中最常见的类型。主要表现为长期、反复的盆腔区域疼痛或不适,持续时间超过3个月,可伴有不同程度的排尿异常症状和性功能障碍,严重影响患者的生活质量;EPS/精液/VB3细菌培养结果阴性。根据EPS/精液/VB3细菌常规显微镜检结果,该型又可再分为ⅢA(炎症性CPPS)和ⅢB(非炎症性CPPS)两种亚型:ⅢA型患者的EPS/精液/VB3中白细胞数量升高;ⅢB型患者的EPS/精液/VB3中白细胞数量在正常范围。Ⅳ型:无症状性前列腺炎(AIP)。无主观症状,仅在有关前列腺方面检查时(EPS、精液、前列腺组织活检及前列腺切术标本的病理检查等)时发现炎症依据。如下表:
慢性前列腺炎归属于中医“精浊”、“白浊”、“白淫”等范畴。古代医家对慢性前列腺炎的病因病机进行探讨,如《素问·痿论篇》:“思想无穷,所愿不得,意淫于外,入房太甚,宗筋弛纵,发为筋痿,及为白淫。”王病注曰:“白物淫衍,如精之状,因溲而下。”清代吴谦《医宗金鉴·杂病心法要诀》明确指出:“浊在清窍溺自清,秽物如脓阴内疼,赤热精竭不及化,白寒湿热败精成。”总的来讲主要分为湿热下注、阴虚火动,肾气亏损、气滞血瘀。观察发现,湿热下注,日久化瘀为是临床主要证型,患者常表现为尿频,尿急,尿痛,且会阴,少腹,小腹等部位刺痛不适,被统称为湿热瘀阻型慢性前列腺炎。临床中长期服用西药(如:左氧氟沙星)会导致胃肠道不适及中枢神经的反应,而口服中药大多为活血软坚、解毒清热之物,长期使用会导致脾胃受损。
发明内容
为了解决上述问题,本发明的目的是提供一种直肠滴注治疗湿热瘀阻型慢性前列腺炎的中药,可有效解决治疗湿热瘀阻型前列腺炎效果好,无副作用的用药问题。
本发明解决的技术方案是,一种直肠滴注治疗湿热瘀阻型慢性前列腺炎的中药,由以下原料药物制成:马鞭草30-40g、凤尾草30-40g,蒲黄30-40g,元胡30-40g,菟丝子30-40g,肉桂5-8g和赤芍25-28g,将原料药物混合在一起,加水400-600mL,室温浸泡25-35分钟,武火煎至沸腾后,改为文火煎煮18-22分钟,过滤,得滤液,即成。
本发明采用纯天然的原料中药物制成,各种药物之间有机配合,协同增效,施药途径科学合理,原料丰富,方法简单,使用方便,疗效好,成本低,是直肠滴注治疗湿热瘀阻型慢性前列腺炎药物上的一大创新。
具体实施方式
以下结合实施例对本发明的具体实施方式作进一步详细说明。
本发明在具体实施中可由以下实施例给出。
实施例1
本发明在具体实施中,一种直肠滴注治疗湿热瘀阻型慢性前列腺炎的中药,由以下原料药物制成:马鞭草33-37g、凤尾草33-37g,蒲黄33-37g,元胡33-37g,菟丝子33-37g,肉桂6-7g和赤芍26-27g,将原料药物混合在一起,置于煎药容器(如药锅、药罐)中,加水400-600mL,室温浸泡25-35分钟,武火煎至沸腾后,改为文火煎煮18-22分钟,过滤,得滤液,即成。
实施例2
本发明在具体实施中,一种直肠滴注治疗湿热瘀阻型慢性前列腺炎的中药,由以下原料药物制成:马鞭草30g、凤尾草30g、蒲黄30g、元胡30g、菟丝子30g、肉桂5g和赤芍25g,将原料药物混合在一起,加水400mL,室温浸泡25-35分钟,武火煎至沸腾后,改为文火煎煮18分钟,过滤,得滤液,即成。
实施例3
本发明在具体实施中,一种直肠滴注治疗湿热瘀阻型慢性前列腺炎的中药,由以下原料药物制成:马鞭草35g、凤尾草35g,蒲黄35g,元胡35g,菟丝子35g,肉桂6g和赤芍26g,将原料药物混合在一起,加水500mL,室温浸泡25-35分钟,武火煎至沸腾后,改为文火煎煮20分钟,过滤,得滤液,即成。
实施例4
本发明在具体实施中,一种直肠滴注治疗湿热瘀阻型慢性前列腺炎的中药,由以下原料药物制成:马鞭草40g、凤尾草40g,蒲黄40g,元胡40g,菟丝子40g,肉桂8g和赤芍28g,将原料药物混合在一起,加水600mL,室温浸泡25-35分钟,武火煎至沸腾后,改为文火煎煮22分钟,过滤,得滤液,即成。
本发明要指出的是,本发明请求保护的技术核心是组方(中药复方),凡是根据本复方中药制成的汤剂、丸剂、粉剂、胶囊剂、片剂,均属于本发明请求保护的范围。
在上述药物中,其中:
马鞭草为马鞭草科植物马鞭草的干燥地上部分。别名凤颈草,紫顶龙芽,铁马鞭,狗牙草,鹤膝风,苦练草,顺捋草、靖蜒草,退血草,土荆芥、野荆芥(《浙江民间常用草药》),本品茎呈方柱形,多分枝,四面有纵沟,长0.5~1m;表面绿褐色,粗糙;质硬而脆,断面有髓或中空。叶对生,皱缩,多破碎,绿褐色,完整者展平后叶片3深裂,边缘有锯齿。穗状花序细长,有小花多数。无臭,味苦。生于河岸草地、荒地、路边、田边及草坡等处。分布全国各地。主产于湖北、广西、贵州等地亦产。6~8月花开时采割,除去杂质,晒干。味苦,性凉。归肝,脾经。功效:清热解毒,活血散瘀,利水消肿。用于治疗外感发热,湿热黄疸,淋病,痈肿疮毒,水肿,痢疾,疟疾,白喉,喉痹,经闭,症瘕,牙疳。现代药理研究发现全草含马鞭草甙,戟叶马鞭草甙,羽扇豆醇,β-谷甾醇,熊果酸,桃叶珊瑚甙,蒿黄素。叶中含马鞭草新甙,腺甙,β-胡萝卜素等。具有抗炎止痛,止咳,兴奋子宫平滑肌的作用。
凤尾草为凤尾蕨科植物凤尾草的全草。别名井口边草,小金星风尾,铁脚鸡,山鸡尾,井茜,井阑草,石长生,凤凰草,井边茜,旋鸡头,阉鸡尾。生长于半阴湿的岩石及墙角石隙中。分布云南、四川、广东、广西、湖南等地。四季可采,洗净,鲜用或晒干用。味淡,微苦,性寒。归肾、胃二经。功效:清热利湿,凉血止血,消肿解毒。用于治疗黄疸型肝炎,肠炎,淋浊,菌痢,带下,吐血,衄血,便血,尿血,扁桃体炎,腮腺炎,痈肿疮毒,湿疹。现代药理研究发现其含有蕨素B、C、F、O、S,蕨素C-3-O-葡萄糖甙,2β、15α-二羟基-对映-16-贝壳杉-烯,2β、16α-二羟基-对映-贝壳杉烷,大叶凤尾甙A、B,芹菜素-7-O-葡萄糖甙,木犀草素-7-O-葡萄糖甙。对金黄色葡萄球菌,大肠杆菌,痢疾杆菌,结核杆菌均有抑制作用。
蒲黄为香蒲科植物水浊香蒲、东方香蒲、或同属植物的干燥花粉。别名蒲厘花粉,蒲花,蒲棒花粉,蒲草黄。全国大部分地区多有生产。夏季采收蒲棒上部的黄色雄花序,晒干后碾轧,筛取花粉。剪取雄花后,晒干。性平,味甘。归肝、新包经。功效:止血,化瘀,通淋。用于治疗血淋涩痛,吐血,衄血,咯血,崩漏,外伤出血,经闭痛经,脘腹刺痛,跌扑肿痛。现代药理研究发现蒲黄中含有大量黄酮类成分如:柚皮素,异鼠李素,槲皮素,香蒲新甙等。能明显增加冠状动脉血流量,降低血脂,防止动脉粥样硬化,提高机体对缺氧的耐受能力。蒲黄水溶部分体外对金黄色葡萄球菌、弗氏痢疾杆菌、绿脓杆菌、大肠杆菌、伤寒杆菌、史密氏痢疾杆菌及2型副伤寒杆菌均有较强的抑制作用。另外,其内含有的黄酮类成分能够抑制血栓的形成。
元胡为罂粟科植物延胡索的干燥块茎。别名延胡(《雷公炮炙论》),玄胡索(《济生方》),元胡索(《药品化义》)。生于山地林,分布河北、山东、江苏、浙江等地。主产浙江。夏初茎叶枯萎时采挖,除去须根,洗净,置沸水中煮至恰无白心时,取出,晒干。性温,味苦、辛。归肝、脾经。功效:活血,利气,止痛。主要用于治疗胸胁、脘腹疼痛,经闭痛经,产后瘀阻,跌扑肿痛。现代药理学研究发现其块茎中含有紫堇碱、dl-四氢掌叶防己碱、原阿片碱、L-四氢黄连碱、dl-四氢黄连碱、L-四氢非洲防己碱、紫堇鳞茎碱、β-高白屈菜碱、黄连碱、去氢紫堇碱,还有紫堇达明碱、去氢紫堇达明碱等。具有明显的止痛,镇静作用。
菟丝子旋花科植物菟丝子的干燥成熟种子。别名豆寄生、无根草、黄丝、黄丝藤、无娘藤、金黄丝子。主产辽宁、吉林、河北、河南、山东、山西、江苏等地。秋季果实成熟时采收植株,晒干,打下种子,除去杂质。性温,味甘。归肝、肾、脾经。功效:滋补肝肾,固精缩尿,安胎,明目,止泻。主要用于治疗阳痿遗精,尿有余沥,遗尿尿频,腰膝酸软,目昏耳鸣,肾虚胎漏,胎动不安,脾肾虚泻;外治白癜风。现代药理研究表明菟丝子主要成分为槲皮素,紫云,金丝桃甙及槲皮素-3-O-β-D-半乳糖-7-O-β-葡萄糖甙(quercetin-3-O-β-D-galactoside-7-O-β-glucoside)。能够使下降的肝糖元和肾上腺抗坏血酸上升,有明显的保护肝脏的作用。实验表明菟丝子水煎剂,能延长小鼠负重游泳时间,增强小鼠在常压下的耐缺氧能力,提高其非特异性抵抗力。
肉桂为樟科植物肉桂的干燥树皮。别名牡桂(《本经》),紫桂(《药性论》),大桂(《唐本草》),辣桂(《仁斋直指方》),桂皮(《本草述》),玉桂(《本草求原》)。栽培于砂土及斜坡山地。主产于广西、广东、云南等地。多于秋季剥取,阴干。性大热,味辛,甘。功效:补火助阳,引火归源,散寒止痛,活血通经。主要用于治疗阳痿,宫冷,腰膝冷痛,肾虚作喘,阳虚眩晕,目赤咽痛,心腹冷痛,虚寒吐泻,寒疝,奔豚,经闭,痛经。现代药理研究表明肉桂中含有挥发油(称桂皮油),主要成分为桂皮醛,并含少量乙酸桂皮酯、乙酸苯丙酯等。有强大杀菌作用,对革兰氏染色刚性菌的效果比阴性者好。并且能够降低血压,缓解疼痛。
赤芍,又名木芍药、草芍药、红芍药、毛果赤芍,为毛茛科植物赤芍或川赤芍的干燥根,主产于四川西昌、甘孜、凉山、阿坝等地,云南、贵州亦产,其中以西昌产者为最优。春、秋二季采挖,除去根茎、须根及泥沙,分开大小,洗净,润透,切园片或斜片,干燥,筛去碎屑,晒干。赤芍是著名野生地道中药材,应用历史悠久,用量较大、用途广泛且需求较为刚性,每年都有相当数量的出口。本品味苦,性微寒,归肝经,具有清热凉血,活血祛瘀之功,主治温毒发斑、吐血衄血、肠风下血、目赤肿痛、痈肿疮疡、闭经、痛经、崩带淋浊、瘀滞胁痛、疝瘕积聚、跌扑损伤等症。现代药理研究发现赤芍中含有含芍药甙,氧化芍药甙,苯甲酰芍药甙,白芍甙,芍药甙无酮,具有减缓心率,抗血小板凝集,抑制血栓形成,降低血脂的作用。
上述药物中马鞭草味苦,性凉。归肝,脾经。能够清热解毒,活血散瘀,利水消肿。为方中君药,前列腺炎日久不愈导致湿热之中又有瘀邪壅阻之像,马鞭草利水消肿,清热解毒使湿邪去,热毒除,其活血化瘀之效使瘀血散疼痛减。《分类草药性》:“去小便血淋肿痛。”《纲目》:“捣涂痈肿及蠼螋尿疮,男子阴肿。”《本草经疏》:“马鞭草,本是凉血破血之药。下部阴疮者,血热之极,兼之湿热,故血污浊而成疮,且有虫也。血凉热解,污浊者破而行之,靡不瘥矣。陈藏器谓其破血杀虫,亦此意耳。”配合凤尾草,取其清热利湿,消肿止痛之功,以助君药之力。传统医学认为“痛则不通,不通则痛”。蒲黄,元胡、赤芍为活血止痛之要药,三药合用荡涤瘀邪,使瘀邪去且痛自除,能够缓解前列腺炎患者会阴,腹股沟,少腹等部位的疼痛不适。菟丝子为固精缩尿的要药,能够改善患者小便频数余沥不尽的症状,《别录》:“养肌强阴,坚筋骨,主茎中寒,精自出,溺有余沥,口苦燥渴,寒血为积。”。辅以肉桂,取其辛热之性,活血通络之功,防诸多寒凉之药扼制瘀邪,并能助菟丝子补肾之功。
全方选药精细、组方严谨、有效组合、配伍得当、协同增效,共奏清热利湿、化瘀止痛之功。该方并经临床应用,取得了良好的效果,其有关资料如下。
1西医诊断标准
根据中国医药科学出版社2012年4月出版的《中药新药治疗慢性前列腺炎的临床研究指导原则》中慢性前列腺炎的西医诊断标准制定:
(1)症状分为两类,一为下尿路刺激症状,二为炎性反应或反射性疼痛症状。具体表现为不同程度的尿频、尿急、尿痛、尿不尽、尿道灼热,晨起、尿末或大便时尿道偶可见有少量白色分泌物,外生殖器、下腹部、耻骨上区、腰骸及肛门周围有坠胀、疼痛感。
(2)前列腺触诊质地腺体饱满或软硬不均,或有炎性结节或质地较韧压痛可有局限性压痛大小可增大正常或缩小。
(3)前列腺液(EPS)镜检:WPS≧10个/HP;卵磷脂小体减少或消失。
凡具备(1),(2),(3)中任意一项即可确诊。
2中医辨证标准
根据中国医药科学出版社2012年4月出版的《中药新药治疗慢性前列腺炎的临床研究指导原则》中慢性前列腺炎的中医诊断标准制定:
湿热下注证
主症:尿频、尿急、尿痛。
次症:尿道灼热,尿道白浊,阴囊潮湿、尿后滴沥、舌红苔黄或黄腻、脉滑。
气滞血瘀证
主症:会阴部、外生殖器区、下腹部、耻骨上区、腰骸及肛门周围坠胀、或以上部位疼痛。
次症:尿后滴沥、尿刺痛、舌质暗或有癖点癖斑、脉弦或涩。
湿热瘀阻证:
主症:尿频,尿急,尿痛。
次症:尿道灼热、刺痛,阴囊潮湿,尿后余沥,会阴部、外生殖器区、下腹部、腹股沟等部位疼痛不适。
3纳入标准
①自愿加入本临床试验研究,并签署知情同意书。
②符合西医慢性前列腺炎的诊断标准。
③符合中医湿热瘀阻型慢性前列腺炎的诊断标准。
④年龄在18-50岁之间的男性患者
4排除标准
①年龄在18岁以下或50岁以上。
②急性前列腺炎。
③良性前列腺增生、前列腺癌,神经原性膀耽、尿道崎形或狭窄及严重的神经官能症,前列腺肿瘤患者。
④以局部疼痛为主要表现的患者,应注意排除下腹,会阴,腰骶等部位的其它病变。如输尿管结石,膀耽结石,腹股沟病,精索静脉曲张,附睾炎,直肠结肠疾病等。
⑤合并有心血管、脑、肝、肾和造血系统严重原发性疾病,过敏体质和对多种药物过敏者。
⑥无法合作者,如精神病患者。
5脱落标准与剔除标准:
5.1退出试验病例标准
①出现过敏反应或严重不良事件者,根据医生判断应该停止者。
②病程中病情恶化,根据医生判断应该停止者。
③患者在临床试验过程中依从性较差,不愿意继续进行治疗者。
5.2病例的脱落与处理
脱落的定义:纳入观察病例,进入随机分组者,无论何时何因退出,只要没有完成方案所规定的观察周期者,均称为脱落病例。未满1个疗程症状消失自行停药者,不作为脱落病例。当受试者脱落后,研究者受试者联系,询问理由、记录最后一次用药时间、完成所能完成的评估项目。因过敏反应、不良反应、治疗无效而退出试验病例,研究者应根据受试者实际情况,采取相应的治疗措施。凡是入选并已使用编号的病人,无论是否脱落,均应记录和保留病例观察表。脱落病人无需另补。所有脱落病例均应将病例观察表等资料汇总,统计分析。
5.3病例的剔除
未按医嘱应用药物治疗者;在随机化之后没有任何数据者给予剔除。
6分组及实验方法
60例筛选合格进入随机化试验的受试者按随机数字表法随机均分为2组,治疗组采用本发明中药治疗,对照组采用翁沥通治疗。本研究采用随机、平行、对照的临床试验方法,研究方案报请医院伦理委员会审批后进行。
7治疗方案
中药直肠滴注组(治疗组)取本发明中药煎剂100mL,用肛管插入病人肛门6~10cm(相当于前列腺沟处),以每分钟60滴缓慢滴入,滴完后嘱患者肛门收缩次,俯卧半小时,尽量保留一个晚上,第二天随大便排出每日一次,28次为一疗程。
口服翁沥通组(对照组)每日3次每次3粒;2组均4周为1个疗程,疗程结束后统计疗效。
8观察指标
8.1安全性观察指标:血、尿、便常规、心电图、肝功能、肾功能检查及不良反应。
8.2疗效性指标:
①主要相关症状。
②前列腺液常规。
③中医症候评分。
④美国国立卫生研究所制定的慢性前列腺疾病症状积分指数(NIH-CPSI)。
附:美国国立卫生研究所指定的慢性前列腺疾病症状积分指数表(NIH-CPSI)
一、疼痛或不适
1.过去一周内下述部位有过疼痛或不适吗? | 有 | 没有 |
①在直肠肛门和睾丸阴囊之间,即会阴部 | 1分 | 0分 |
②睾丸 | 1分 | 0分 |
③阴茎的头部(与排尿无关) | 1分 | 0分 |
④腰部以下,膀胱或耻骨区 | 1分 | 0分 |
2.过去的一周,你是否经历过以下事件。 | 有 | 没有 |
①排尿时有尿道烧灼感或疼痛 | 1分 | 0分 |
②在性高潮后晰精或性生活期间有疼痛和不适? | 1分 | 0分 |
9综合疗效评定标准根据中国医药科学出版社2012年4月出版的《中药新药治疗慢性前列腺炎的临床研究指
导原则》中慢性前列腺炎的疗效标准制定:
(1)临床痊愈:NIH-CPSI积分减少70%以上,中医症候评分较治疗前减少90%以上,前列腺液检查白细胞正常或<+;
(2)显效:NIH-CPSI积分减少50-69%,中医症候评分较治疗前减少60%-89%,前列腺液检查:白细胞减少1/2以上。
(3)有效:NIH-CPSI积分减少30-49%,中医症候评分较治疗前减少30%-59%,前列腺液检查:白细胞较前减少。
(4)无效:NIH-CPSI积分减少30%以下,中医症候评分较治疗前减少30%以下,前列腺液检查:白细胞较治疗前无改善。
上述三项必须同时具备,如一项达不到指标,下降一个指标。
10统计方法
①计量资料:先进行正态性检验,符合正态分布者进行t检验或方差分析,方差分析前进行方差齐性检验。两组间比较采用t检验,不符合正态性分布者则采用两组间秩和检验;组内治疗前后自身比较采用配对t检验(Paired-Samples T Test),不符合正态性分布者则采用配对秩和检验(2Related Samples,Wilcoxon法)。多组间两两比较符合正态性分布、方差齐者采用方差分析(one-way ANOVA),两两组间比较用LSD法;不符合正态分布或方差不齐者用Wilcoxon秩和检验。
②计数资料:采用秩和检验,两两比较用Wilcoxon秩和检验;两个以上组间比较用Kruskal-Wallis检验。两个总体率(或构成比)之间比较,用χ2检验或确切概率法,多个样本率或构成比之间比较,采用列联表χ2检验。
③等级资料:采用Kruskal-Wallis H检验。
11统计学处理
11.1总体疗效判定
本发明中药治疗组30例中,痊愈5例,显效15例,有效6例,无效4例,总有效率86.7%。对照组30例,痊愈3例,显效8例,有效10例,无效9例,总有效率70.0%。经统计学处理显示两组疗效差异具有统计学意义(P<0.05)。见表1
表1两组综合疗效比较
11.2两组患者治疗前后NIH-CPSI积分比较,见表2
表2两组治疗前后NIH-CPSI积分比较
11.3两组患者治疗前后中医症候评分比较。见表3
11.4两组患者治疗前后EPS白细胞比较。见表4
表4两组治疗前后EPS白细胞比较
11.5安全性指标异常率情况:
经统计学处理,治疗组和对照组各项安全性指标血、尿、粪常规、心电图、肝功、肾功,肝胆B超,治疗前后比较均无显著差异(P>0.05)。
11.6不良反应:
在用药的不同阶段,两组患者均无明显不良反应发生。血、尿、便常规、心电图、肝功能、肾功能检查未见明显异。
结论
由上述表明,本发明中药稳定可靠,治疗效果好,见效快,无毒副作用,在治疗湿热瘀阻型前列腺炎上,能明显缓解患者小便频数、尿余沥、下腹部疼痛,会阴部胀痛,小便灼热刺痛等症状,减少NIH-CPSI积分,为湿热瘀阻型前列腺炎提供了良好的治疗方法,有效率达到86.7%,是中医药学上的一大创造,有实际的临床意义,是治疗湿热瘀阻型前列腺炎药物上的一大创新,有良好的社会和经济效益。
Claims (5)
1.一种直肠滴注治疗湿热瘀阻型慢性前列腺炎的中药,其特征在于,由以下原料药物制成:马鞭草30-40g、凤尾草30-40g,蒲黄30-40g,元胡30-40g,菟丝子30-40g,肉桂5-8g和赤芍25-28g,将原料药物混合在一起,加水400-600mL,室温浸泡25-35分钟,武火煎至沸腾后,改为文火煎煮18-22分钟,过滤,得滤液,即成。
2.根据权利要求1所述的直肠滴注治疗湿热瘀阻型慢性前列腺炎的中药,其特征在于,由以下原料药物制成:马鞭草33-37g、凤尾草33-37g,蒲黄33-37g,元胡33-37g,菟丝子33-37g,肉桂6-7g和赤芍26-27g,将原料药物混合在一起,置于煎药容器中,加水400-600mL,室温浸泡25-35分钟,武火煎至沸腾后,改为文火煎煮18-22分钟,过滤,得滤液,即成。
3.根据权利要求1所述的直肠滴注治疗湿热瘀阻型慢性前列腺炎的中药,其特征在于,由以下原料药物制成:马鞭草30g、凤尾草30g、蒲黄30g、元胡30g、菟丝子30g、肉桂5g和赤芍25g,将原料药物混合在一起,加水400mL,室温浸泡25-35分钟,武火煎至沸腾后,改为文火煎煮18分钟,过滤,得滤液,即成。
4.根据权利要求1所述的直肠滴注治疗湿热瘀阻型慢性前列腺炎的中药,其特征在于,由以下原料药物制成:马鞭草35g、凤尾草35g,蒲黄35g,元胡35g,菟丝子35g,肉桂6g和赤芍26g,将原料药物混合在一起,加水500mL,室温浸泡25-35分钟,武火煎至沸腾后,改为文火煎煮20分钟,过滤,得滤液,即成。
5.根据权利要求1所述的直肠滴注治疗湿热瘀阻型慢性前列腺炎的中药,其特征在于,由以下原料药物制成:马鞭草40g、凤尾草40g,蒲黄40g,元胡40g,菟丝子40g,肉桂8g和赤芍28g,将原料药物混合在一起,加水600mL,室温浸泡25-35分钟,武火煎至沸腾后,改为文火煎煮22分钟,过滤,得滤液,即成。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910215999.4A CN109718311B (zh) | 2019-03-21 | 2019-03-21 | 一种直肠滴注治疗湿热瘀阻型慢性前列腺炎的中药 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910215999.4A CN109718311B (zh) | 2019-03-21 | 2019-03-21 | 一种直肠滴注治疗湿热瘀阻型慢性前列腺炎的中药 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN109718311A CN109718311A (zh) | 2019-05-07 |
CN109718311B true CN109718311B (zh) | 2021-06-22 |
Family
ID=66302771
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201910215999.4A Expired - Fee Related CN109718311B (zh) | 2019-03-21 | 2019-03-21 | 一种直肠滴注治疗湿热瘀阻型慢性前列腺炎的中药 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN109718311B (zh) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101195011A (zh) * | 2007-11-28 | 2008-06-11 | 韩曙光 | 一种治疗前列腺炎、增生的中药 |
CN103041263A (zh) * | 2012-12-31 | 2013-04-17 | 青岛华仁信息技术开发有限公司 | 一种治疗慢性前列腺炎的中药直肠给药栓剂及其制备方法 |
CN104056203A (zh) * | 2014-07-03 | 2014-09-24 | 孙自学 | 一种治疗湿热瘀阻型慢性前列腺炎的外用中药 |
CN108969642A (zh) * | 2018-05-29 | 2018-12-11 | 江西中医药大学 | 一种治疗慢性前列腺炎的中药复方外用制剂及其制备工艺 |
-
2019
- 2019-03-21 CN CN201910215999.4A patent/CN109718311B/zh not_active Expired - Fee Related
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101195011A (zh) * | 2007-11-28 | 2008-06-11 | 韩曙光 | 一种治疗前列腺炎、增生的中药 |
CN103041263A (zh) * | 2012-12-31 | 2013-04-17 | 青岛华仁信息技术开发有限公司 | 一种治疗慢性前列腺炎的中药直肠给药栓剂及其制备方法 |
CN104056203A (zh) * | 2014-07-03 | 2014-09-24 | 孙自学 | 一种治疗湿热瘀阻型慢性前列腺炎的外用中药 |
CN108969642A (zh) * | 2018-05-29 | 2018-12-11 | 江西中医药大学 | 一种治疗慢性前列腺炎的中药复方外用制剂及其制备工艺 |
Also Published As
Publication number | Publication date |
---|---|
CN109718311A (zh) | 2019-05-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2474314B1 (en) | Antiphlogistic, antioncotic and analgesic chinese herbal composition preparative method and usage thereof | |
CN102178804B (zh) | 一种治疗肛周湿疹的中药组合物及其制备方法 | |
CN104352991A (zh) | 一种治疗痛风的中药制剂及其制备方法 | |
CN104857359A (zh) | 一种治疗仔猪痢疾的药物组合物及其制备方法 | |
CN101095761A (zh) | 治疗阑尾炎的中药及其制备方法 | |
CN104547188A (zh) | 一种治疗静脉曲张的外用制剂及其制备方法 | |
CN102018807A (zh) | 一种治疗妇科滴虫性阴道炎的药物组合物及其制备方法 | |
CN109718311B (zh) | 一种直肠滴注治疗湿热瘀阻型慢性前列腺炎的中药 | |
CN105727110A (zh) | 一种治疗妇科炎症的中药洗液及其制备方法 | |
CN104587402B (zh) | 一种治疗慢性盆腔炎的中药制剂及其制备方法 | |
CN107648516B (zh) | 一种治疗湿热下注型慢性非淋菌性尿道炎的中药及其制备方法 | |
CN104971271A (zh) | 一种治疗瘀湿化热型前列腺增生的药物及制备方法 | |
CN105168662A (zh) | 一种治疗肾结石的通淋排石的中药制剂及其制备方法 | |
CN105169233B (zh) | 一种治疗结石的中药组合物 | |
CN103800745A (zh) | 一种治疗湿热瘀阻型慢性盆腔疼痛综合征的中药 | |
CN104096103A (zh) | 一种治疗癃闭的中药药剂 | |
CN113797283B (zh) | 一种治疗痔疮的中药栓剂及其制备方法 | |
CN116159110B (zh) | 一种化湿清斑复方中药在治疗贝赫切特病中的新用途 | |
CN107375636B (zh) | 一种治疗肾虚血瘀型阳痿的中药及其制备方法 | |
CN105999112B (zh) | 一种治疗慢性前列腺炎及前列肥大的中药组合物及其制备方法 | |
CN104338086A (zh) | 一种治疗慢性子宫内膜炎的中药灌肠剂及其制备方法 | |
CN105641438A (zh) | 一种治疗血瘀肠络型溃疡性结肠炎的中药及制备方法 | |
CN105169275A (zh) | 一种保肝利胆的大黄口服液及其制备方法 | |
CN104547922A (zh) | 一种用于治疗前列腺炎的中药组合物及其制备方法 | |
CN115554372A (zh) | 一种治疗原发性纤维肌痛综合征的中药及制备方法和应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20210622 |